Medications for Non-Radiographic Axial Spondyloarthritis

Non-radiographic axial spondyloarthritis (nr-axSpA) is a chronic inflammatory rheumatic disease characterized by inflammatory back pain and other axial or peripheral manifestations without definite radiographic sacroiliitis. Treatment aims to reduce pain and stiffness, preserve physical function, control inflammation, and limit disease burden. Clinical decision-making depends on symptom activity, objective signs of inflammation, comorbidities, safety considerations, patient preferences, and access to specialist care. Management generally combines exercise and education with pharmacological therapy, while diagnosis and treatment remain challenging because symptoms can overlap with mechanical back pain and structural changes may be absent on conventional radiographs.

The therapeutic landscape is evolving from symptom relief alone toward sustained control of inflammation and function. Nonsteroidal anti-inflammatory drugs remain an important initial pharmacological option for many patients, while biologic and targeted synthetic therapies are considered when disease activity persists despite appropriate conventional management and objective inflammation supports escalation. Guideline-based care increasingly emphasizes shared decision-making, regular assessment of disease activity and function, screening for infection and comorbidity, and adjustment of therapy when response is inadequate or tolerability is poor. Non-pharmacological measures, including structured exercise, posture and mobility work, smoking cessation, and management of cardiovascular, gastrointestinal, ocular, and dermatological comorbidities, remain integral to outcomes.

Artificial intelligence may help address persistent diagnostic and monitoring challenges by identifying patterns in clinical records, magnetic resonance imaging, radiographs, laboratory results, and patient-reported outcomes. Potential applications include triaging patients with inflammatory back pain, supporting image interpretation, detecting changes in disease activity, and identifying individuals at risk of inadequate response or treatment interruption. However, these tools require representative training data, external validation, transparent performance measures, and safeguards against automation bias. AI should support-not replace-rheumatologist judgment, particularly where symptoms, imaging findings, comorbidities, pregnancy considerations, infection risk, and patient preferences must be integrated.

Across North America, established specialist networks and access to advanced therapies coexist with payer authorization requirements and uneven affordability. Europe benefits from mature rheumatology guidance and coordinated regulatory systems, although reimbursement rules and diagnostic pathways differ among countries. Asia-Pacific combines advanced care in markets such as Australia, Japan, and South Korea with substantial variation in specialist availability and diagnostic capacity across the region. Latin America faces disparities in access to imaging, rheumatology services, and innovative medicines, while public and private pathways can differ considerably. In the Middle East, specialist concentration and reimbursement policies influence continuity of care, and in Africa, limited diagnostic infrastructure, workforce constraints, and medicine availability can delay diagnosis and treatment escalation.

ASEAN countries show diverse regulatory environments, healthcare financing models, and specialist capacity, making local access strategies and diagnostic education important. BRICS members encompass wide differences in public procurement, insurance coverage, biosimilar use, and rheumatology infrastructure, with affordability and treatment continuity remaining central considerations. European Union systems generally operate within shared regulatory principles but retain national reimbursement and clinical implementation decisions. G7 health systems typically have substantial specialist and research capacity, yet face cost, waiting-time, and geographic-access pressures. GCC countries often have concentrated specialist services and expanding investment in advanced care, while continuity may depend on national coverage rules and referral pathways. NATO membership does not define a uniform healthcare model, but participating countries may share preparedness, procurement, and cross-border health policy considerations relevant to resilient supply and care delivery.

Australia combines specialist rheumatology services with geographically uneven access and a structured public reimbursement environment. Brazil and Mexico face marked variation between urban specialist care and underserved areas, with affordability and diagnostic access influencing treatment decisions. Canada and the United States have advanced specialist capacity but may encounter regional disparities, prior authorization, and out-of-pocket barriers. China and India are expanding rheumatology and imaging capacity, while access remains heterogeneous across provinces, cities, and income groups. France, Germany, Italy, and Spain have established clinical expertise and public health coverage, but referral processes, regional administration, and reimbursement implementation differ. The United Kingdom has national guidance and specialist services, with waiting times and commissioning decisions affecting access. Japan and South Korea have strong healthcare infrastructure, although diagnostic recognition, local prescribing practice, and coverage requirements shape uptake. Russia’s care pathways are influenced by regional health-system capacity, medicine access, and economic conditions.

Industry leaders should support earlier recognition by educating primary-care and musculoskeletal clinicians about inflammatory back pain and appropriate referral criteria. Evidence generation should reflect nr-axSpA populations, include patient-reported function and quality of life, and distinguish treatment effects across relevant comorbidities and imaging profiles. Access strategies should align with local reimbursement rules, responsible use of biosimilars where appropriate, and transparent value communication rather than relying on broad assumptions about treatment uptake. Patient-support programs should prioritize adherence, injection or administration education, infection-risk awareness, vaccination discussions, and rapid management of adverse events. Organizations developing digital or AI-enabled tools should validate them across diverse populations, monitor bias, protect health data, and demonstrate clinical usefulness in routine care.

This executive summary synthesizes established clinical principles for nr-axSpA using evidence categories that include international and national treatment guidelines, regulatory prescribing information, peer-reviewed clinical studies, health-system publications, and publicly available epidemiological and access literature. The assessment considers disease recognition, pharmacological sequencing, non-pharmacological care, safety monitoring, diagnostic infrastructure, reimbursement, and regional variation. Geographic comparisons are qualitative and are intended to describe care environments rather than quantify commercial opportunity. Interpretation should account for differences in diagnostic definitions, study populations, healthcare organization, approval status, and local clinical practice.

Management of nr-axSpA is increasingly centered on timely diagnosis, objective assessment of inflammation, individualized treatment selection, and sustained attention to function and quality of life. Medication decisions are most effective when combined with exercise, education, comorbidity management, and regular reassessment. Regional and national differences in specialist capacity, imaging, reimbursement, and affordability will continue to shape patient experience. Leaders who strengthen diagnostic pathways, generate clinically relevant evidence, improve equitable access, and apply digital tools responsibly can help close persistent gaps in care without compromising safety or shared decision-making.